A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...
ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...
We’re excited to present a review of our robust data package at OIS, highlighting our momentum toward advancing this innovation into clinical evaluation.” About VLTR-559 VLTR-559 is a long-acting anti ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
On track to report topline 56-week data for LUGANO in mid-2026 with LUCIA data to closely follow – WATERTOWN, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a ...
The gene therapy will utilize the firm's suprachoroidal vector coAAV-SCS, which it says will be an effective and less burdensome treatment alternative.
Outlook Therapeutics Inc. (NASDAQ:OTLK) surged 17.2% in premarket trading Thursday after announcing that the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback